Guardant Health (NASDAQ:GH) Coverage Initiated at Mizuho

Stock analysts at Mizuho initiated coverage on shares of Guardant Health (NASDAQ:GH - Get Free Report) in a report issued on Thursday, MarketBeat reports. The firm set an "outperform" rating and a $55.00 price target on the stock. Mizuho's price objective points to a potential upside of 21.95% from the stock's previous close.

A number of other brokerages have also commented on GH. Stifel Nicolaus increased their price objective on shares of Guardant Health from $45.00 to $53.00 and gave the stock a "buy" rating in a report on Friday, February 21st. Canaccord Genuity Group increased their price target on shares of Guardant Health from $42.00 to $60.00 and gave the company a "buy" rating in a research note on Monday, February 24th. Guggenheim reiterated a "buy" rating and issued a $56.00 price objective on shares of Guardant Health in a research report on Monday, February 24th. Morgan Stanley boosted their target price on Guardant Health from $42.00 to $52.00 and gave the stock an "overweight" rating in a research report on Thursday, March 6th. Finally, Scotiabank lifted their price objective on Guardant Health from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research report on Monday, February 24th. Twenty equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Guardant Health has a consensus rating of "Buy" and an average target price of $49.00.

Remove Ads

Guardant Health Trading Down 0.1 %

Shares of Guardant Health stock traded down $0.06 during mid-day trading on Thursday, reaching $45.10. 829,365 shares of the stock were exchanged, compared to its average volume of 2,137,104. The company has a market cap of $5.57 billion, a price-to-earnings ratio of -12.67 and a beta of 1.45. Guardant Health has a fifty-two week low of $15.81 and a fifty-two week high of $50.89. The firm has a 50-day simple moving average of $43.53 and a 200 day simple moving average of $35.93.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.15). Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The business had revenue of $201.81 million during the quarter, compared to analyst estimates of $192.50 million. On average, research analysts predict that Guardant Health will post -2.9 EPS for the current fiscal year.

Institutional Investors Weigh In On Guardant Health

Several institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in shares of Guardant Health by 3.0% during the fourth quarter. Vanguard Group Inc. now owns 12,052,551 shares of the company's stock worth $368,205,000 after buying an additional 350,606 shares during the period. Deep Track Capital LP grew its position in Guardant Health by 7.0% in the fourth quarter. Deep Track Capital LP now owns 6,419,566 shares of the company's stock valued at $196,118,000 after purchasing an additional 419,006 shares in the last quarter. Geode Capital Management LLC raised its holdings in Guardant Health by 1.1% during the third quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company's stock worth $64,754,000 after acquiring an additional 29,686 shares in the last quarter. Two Sigma Advisers LP grew its stake in shares of Guardant Health by 96.7% in the fourth quarter. Two Sigma Advisers LP now owns 2,315,600 shares of the company's stock valued at $70,742,000 after buying an additional 1,138,300 shares in the last quarter. Finally, Two Sigma Investments LP grew its position in shares of Guardant Health by 38.5% in the 4th quarter. Two Sigma Investments LP now owns 1,890,714 shares of the company's stock valued at $57,761,000 after acquiring an additional 525,368 shares during the period. 92.60% of the stock is owned by institutional investors.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.